Suramin (Generic (no specific brand names for cancer treatment))

Other Medications

ES Not available 1 Clinical Trials

Description

Suramin is an antiparasitic drug that has been investigated experimentally for various cancers, including colorectal cancer, though it is not approved for this indication. It was originally developed to treat African sleeping sickness and river blindness but has shown potential anticancer properties in research studies.

Mechanism of Action

Suramin works by inhibiting multiple growth factors and enzymes involved in cell proliferation and angiogenesis, potentially blocking tumor growth and blood vessel formation.

Side Effects

Peripheral neuropathy Fatigue and weakness Adrenal insufficiency Coagulopathy (bleeding disorders)

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00003038 Phase 1
Archived
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
United States